Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 ...

LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an ...

IMUNON (IMNN) announced that an abstract highlighting new, highly encouraging, Overall Survival data from the Phase 2 OVATION 2 Study of ...

Short interest in Imunon Inc (NASDAQ:IMNN) increased during the last reporting period, rising from 997.88K to 1.20M. This put 8.29% of the company's publicly available shares short. Short interest ...

At close: April 17 at 4:00:02 PM EDT ...

Imunon, Inc. (NASDAQ:IMNN – Get Free Report)’s share price dropped 1.9% during trading on Wednesday .The company traded as low as $0.86 and last traded at $0.86. Approximately 30,040 shares ...

Visit Nature's Fynd at Booth 1385, in the Organic & Natural Pavilion, South Hall, at the 2025 National Restaurant Association ...